245 related articles for article (PubMed ID: 15162895)
21. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
22. Glimepiride in type 2 diabetes mellitus: a review of the worldwide therapeutic experience.
Massi-Benedetti M
Clin Ther; 2003 Mar; 25(3):799-816. PubMed ID: 12852703
[TBL] [Abstract][Full Text] [Related]
23. Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis.
Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Jain A; Atreja A; Zimmerman RS
Diabetes Obes Metab; 2012 Sep; 14(9):803-9. PubMed ID: 22486923
[TBL] [Abstract][Full Text] [Related]
24. Incretin hormones and maturity onset diabetes of the young--pathophysiological implications and anti-diabetic treatment potential.
Østoft SH
Dan Med J; 2015 Sep; 62(9):. PubMed ID: 26324089
[TBL] [Abstract][Full Text] [Related]
25. Glimepiride: evidence-based facts, trends, and observations (GIFTS). [corrected].
Basit A; Riaz M; Fawwad A
Vasc Health Risk Manag; 2012; 8():463-72. PubMed ID: 23028231
[TBL] [Abstract][Full Text] [Related]
26. Extrapancreatic effects of sulfonylureas--a comparison between glimepiride and conventional sulfonylureas.
Müller G; Satoh Y; Geisen K
Diabetes Res Clin Pract; 1995 Aug; 28 Suppl():S115-37. PubMed ID: 8529504
[TBL] [Abstract][Full Text] [Related]
27. [Clinical efficacy of glimepiride].
Kaneko T; Sakamoto N
Nihon Rinsho; 1997 Nov; 55 Suppl():152-7. PubMed ID: 9434460
[No Abstract] [Full Text] [Related]
28. The effects of acute exercise on metabolic control in type II diabetic patients treated with glimepiride or glibenclamide.
Massi-Benedetti M; Herz M; Pfeiffer C
Horm Metab Res; 1996 Sep; 28(9):451-5. PubMed ID: 8911982
[TBL] [Abstract][Full Text] [Related]
29. [Clinical utilization of combined rosiglitazone and glimepiride in the treatment of type 2 diabetes mellitus].
Fehér J; Lengyel G
Orv Hetil; 2007 Dec; 148(49):2331-5. PubMed ID: 18048112
[TBL] [Abstract][Full Text] [Related]
30. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial.
Nissen SE; Nicholls SJ; Wolski K; Nesto R; Kupfer S; Perez A; Jure H; De Larochellière R; Staniloae CS; Mavromatis K; Saw J; Hu B; Lincoff AM; Tuzcu EM;
JAMA; 2008 Apr; 299(13):1561-73. PubMed ID: 18378631
[TBL] [Abstract][Full Text] [Related]
31. Does insulin preserve beta-cell function in type 2 diabetes?
Heise T; Sawicki PT
J Intern Med; 2002 Apr; 251(4):283-5. PubMed ID: 11952878
[No Abstract] [Full Text] [Related]
32. Characterization of the molecular mode of action of the sulfonylurea, glimepiride, at beta-cells.
Kramer W; Müller G; Geisen K
Horm Metab Res; 1996 Sep; 28(9):464-8. PubMed ID: 8911984
[TBL] [Abstract][Full Text] [Related]
33. Clinical review of glimepiride.
McCall AL
Expert Opin Pharmacother; 2001 Apr; 2(4):699-713. PubMed ID: 11336617
[TBL] [Abstract][Full Text] [Related]
34. Adding glimepiride to insulin+metformin in type 2 diabetes of more than 10 years' duration--a randomised, double-blind, placebo-controlled, cross-over study.
Nybäck-Nakell Å; Adamson U; Lins PE; Landstedt-Hallin L
Diabetes Res Clin Pract; 2014 Feb; 103(2):286-91. PubMed ID: 24485398
[TBL] [Abstract][Full Text] [Related]
35. Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes.
Feinglos MN; Thacker CH; English J; Bethel MA; Lane JD
Diabetes Care; 1997 Oct; 20(10):1539-42. PubMed ID: 9314631
[TBL] [Abstract][Full Text] [Related]
36. Role of sulfonylureas in non-insulin-dependent diabetes mellitus: Part I--"The pros".
Waldhäusl W
Horm Metab Res; 1996 Sep; 28(9):517-21. PubMed ID: 8911990
[No Abstract] [Full Text] [Related]
37. Effects of glimepiride on insulin secretion and sensitivity in patients with recently diagnosed type 2 diabetes mellitus.
Kabadi MU; Kabadi UM
Clin Ther; 2004 Jan; 26(1):63-9. PubMed ID: 14996518
[TBL] [Abstract][Full Text] [Related]
38. Relationship between plasma leptin and plasma insulin levels in type-2 diabetic patients before and after treatment with glibenclamide and glimepiride.
Bhattacharya SK; Madan M; Mahajan P; Paudel KR; Rauniar GP; Das BP; Roy RK
Indian J Physiol Pharmacol; 2008; 52(1):43-52. PubMed ID: 18831351
[TBL] [Abstract][Full Text] [Related]
39. Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients.
Derosa G; Bonaventura A; Bianchi L; Romano D; Fogari E; D'Angelo A; Maffioli P
Metabolism; 2014 Jul; 63(7):957-67. PubMed ID: 24874591
[TBL] [Abstract][Full Text] [Related]
40. The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis.
Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Jain A; Atreja A; Zimmerman RS
Diabetes Care; 2010 Jun; 33(6):1224-9. PubMed ID: 20215447
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
